News

Today, ImmunoFree, Inc. announced that Dr. Ephraim Fuchs has been appointed the Chief Medical Officer of ImmunoFree. In his role as CMO, Dr. Fuchs will oversee all medical and scientific affairs of the company and be responsible for the development of the ImmunoFree tolerance protocol for the 1,000,000+ transplant recipients worldwide who can benefit from…

While kidney transplantation has traditionally required recipients to take immunosuppressive drugs for the remainder of their lives to prevent organ rejection, a new study offers hope for a treatment that may enable transplant recipients to take lower dosages of these drugs, or even none at all. The study, published in Clinical Transplantation in August 2023,…

ImmunoFree, Inc. announced today that it has acquired all rights to FCR001, a cellular therapy product, and the sponsorship of the FREEDOM-1 Study formerly owned by Talaris Therapeutics (TALS). ImmunoFree has assumed all financial and regulatory responsibilities related to these clinical trials. Effective immediately, ImmunoFree will oversee all remaining close-out activities and the shutdown of…

Today the National Kidney Registry announced the activation of its 2,000th patient microsite. The microsite program provides free websites and coaching to transplant patients seeking a living donor. The theory behind the microsite program is that if a patient can direct potential donors to a website that effectively tells their story, they will connect with…

A transfusion of mesenchymal stem cells stabilized and, in some cases, improved transplanted lung function in patients with chronic organ rejection.

Two lingering organ transplantation problems remain – supply and immunosuppressive medication.

Using a method they developed for stem cell transplants, a Stanford team has enabled children with immune disorders to receive a new immune system and a matching kidney from a parent.